FY25 is in the books — sort of
Futura Medical, the company behind Eroxon, put out an unaudited trading update for the year ended 31 December 2025. That makes this less of a flashy “beat the Street” moment and more of a check-in on whether the business is still moving in the direction management promised.
The key number: revenue
Back in September, the company said it expected FY25 revenue to land somewhere between £1.3 million and £1.4 million. That’s the number investors will be anchoring to here, because when a small-cap consumer healthcare story is trying to prove itself, every pound counts. Miss that runway and the market can get twitchy fast; hit it and you at least keep the “maybe this thing has legs” narrative alive.
Why investors should care
For a company built around commercializing sexual health products globally, the whole investment case lives and dies on execution. You’re not just watching sales — you’re watching whether Eroxon is turning into a real commercial engine instead of a science project with a nice logo.
Big picture
This is the kind of update that won’t set off fireworks, but it can quietly change sentiment if the company is showing momentum, or remind everyone that scaling a consumer-health brand is harder than it looks on a pitch deck. Big picture: Futura still has to prove the market is more than intrigued — it has to buy.